Pharmaceutical stocks rose sharply in the first half of the year, can the second half continue to buy?

Since the first half of 2020, the a-share medical sector has performed very brightly, with 341 companies doubling their share prices, mainly in the pharmaceutical biology and medical sector, according to the dataAmong them, this year's listing of Wantai biological growth is higher, more than 2500%, and British Health Care followed closely, in the recent market turmoil during the counter-trend boardIn addition, according to industry statistics, as of July 15, the Value of the A stock market to break 100 billion pharmaceutical stocks also once again hit a new high, reached 13These 13 enterprises cover innovative drugs, medical devices, medical services, Chinese medicine, vaccines and other sub-sectorsJudging from the above data, the first half of the pharmaceutical stocks are very strong, share prices have hit a new highIn this case, for the investors in the pharmaceutical stocks, it raises a very real question: after the big rise, the pharmaceutical stocks can not buy? How do I buy it? The author consults the industry and finds that the general view of the industry is to buy! Just after the big rally, pharmaceutical stocks need to look for areas of apparent valueBecause in the long run, as long as the fundamentals of a pharmaceutical company are not a problem, its market value still reflects its valueAnd it is well known that the pharmaceutical industry has both "must-have consumer attributes and scientific and technological innovation attributes", so in the future for a long time, the pharmaceutical sector will still be China into the stock economy era of rare excellent trackIt is worth noting that in the selection of pharmaceutical stocks, it is necessary to focus on the incidence and drug use of relatively large sub-areasFirst, abandon those industries with more obvious ceilings and focus on the sector's vast sub-sectors, such as pharmaceutical companies that treat kidney disease, liver disease, cancer and cardiovascular diseaseThis is mainly because, from the current supply side of the pharmaceutical industry, many new technologies continue to appear, previously unable to solve the disease, now through some innovative drugs and innovative medical equipment can be treated, and with the development of urbanization, social survival pressure, as well as aging and other factors, the incidence of many diseases gradually increased, and economic development, social wealth, income levels, but also for these areas of drug use amount to provide a broader space for developmentIn addition, industry experts believe that the current first half of the pharmaceutical industry situation, the overall policy direction and direction of development has been basically established, most areas of performance is expected to continue the first half of the performanceIn the core pharmaceutical and even device sector, the general direction of health insurance control fees has been determined, specific measures such as payment method reform (DRGs), adjustment of expenditure structure (restriction of auxiliary drug use, dynamic adjustment of medical insurance catalog), drug price reduction (belt procurement) are in an orderly progressAnd in this case, the superposition of the drug supervision system to encourage innovative drugs, combined with the aging of the population, macroeconomics and other external environment, the second half of 2020 can rise largely should be innovation-oriented, clinical efficacy for Wang's relevant pharmaceutical stocksIn addition, combined with the essence of the industry and overseas market performance, medical services, pharmacies and other fields are in the expansion and rapid growth stage of the horse-running circle, it is estimated that the second half of the strong vaccines, blood products, CRO, medical services and pharmacies and other sectors will be high business climate rise phenomenon